Response to Sir Michael Rawlins' comments 30/07/2018

In response to comments made by Sir Michael Rawlins (Chair of the MHRA) to The Pharmaceutical Journal on 27th July 2018, Wockhardt UK would like to clarify that Brexit will have no effect on the manufacture and supply of Hypurin® insulin in the UK.